Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials

BACKGROUND: Plaque psoriasis affects ~ 1% of the pediatric population, negatively impacting quality of life. The efficacy and safety of secukinumab in pediatric patients with moderate to severe or severe chronic plaque psoriasis have been established in two pivotal phase 3 trials (open-label, NCT036...

Descripción completa

Detalles Bibliográficos
Autores principales: Sticherling, Michael, Nikkels, Arjen F., Hamza, Ashraf M., Kwong, Pearl, Szepietowski, Jacek C., El Sayed, Mahira, Ghislain, Pierre-Dominique, Khotko, Alkes A., Patekar, Manmath, Ortmann, Christine-Elke, Forrer, Pascal, Papanastasiou, Philemon, Keefe, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460311/
https://www.ncbi.nlm.nih.gov/pubmed/37341961
http://dx.doi.org/10.1007/s40257-023-00782-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460311/
https://www.ncbi.nlm.nih.gov/pubmed/37341961
http://dx.doi.org/10.1007/s40257-023-00782-8

Ejemplares similares